Myriad Genetics
Update in progressMYGN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops molecular tests for oncology, women’s health, pharmacogenomics, and prenatal screening. Its portfolio includes BRACAnalysis CDx, MyRisk, MyChoice CDx, Prolaris, EndoPredict, Precise Tumor Molecular Profile, Prequel Prenatal Screen, Foresight Carrier Screen, SneakPeek Early Gender, FirstGene, and GeneSight. It collaborates with Illumina and major medical centers. Founded 1991, based in Salt Lake City.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.29
- Governance
- -0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!